References
- CancerNet . Pancreatic cancer: statistics. www.cancer.net/cancer-types/pancreatic-cancer/statistics
- Bekkali NLH , OppongKW. Pancreatic ductal adenocarcinoma epidemiology and risk assessment: could we prevent? Possibility for an early diagnosis. Endosc. Ultrasound6(Suppl. 3), S58–S61 (2017).
- Rahib L , SmithBD, AizenbergR, RosenzweigAB, FleshmanJM, MatrisianLM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res.74(11), 2913–2921 (2014).
- Bansal P , SonnenbergA. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology109(1), 247–251 (1995).
- American Cancer Society . Pancreatic cancer risk factors. www.cancer.org/cancer/pancreatic-cancer/causes-risks-prevention/risk-factors.html
- Talamini G , BassiC, FalconiMet al. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig. Dis. Sci.44(7), 1303–1311 (1999).
- Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116(2), 281–297 (2004).
- Calin GA , CroceCM. MicroRNA signatures in human cancers. Nat. Rev. Cancer6(11), 857–866 (2006).
- Harbuzariu A , Oprea-IliesGM, Gonzalez-PerezRR. The role of Notch signaling and leptin–Notch crosstalk in pancreatic cancer. Medicines (Basel)5(3), 68 (2018).
- Gao J , LongB, WangZ. Role of Notch signaling pathway in pancreatic cancer. Am. J. Cancer Res.7(2), 173–186 (2017).
- Guo H , LuY, WangJet al. Targeting the Notch signaling pathway in cancer therapeutics. Thorac. Cancer5(6), 473–486 (2014).
- Majidinia M , DarbandSG, KavianiM, NabaviSM, Jahanban-EsfahlanR, YousefiB. Cross-regulation between Notch signaling pathway and miRNA machinery in cancer. DNA Repair (Amst.)66–67, 30–41 (2018).
- Carter JT , GrenertJP, RubensteinL, StewartL, WayLW. Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J. Am. College Surgeons207(2), 210–218 (2008).
- Warshaw AL , Fernández-delCastillo C. Pancreatic carcinoma. N. Engl. J. Med.326(7), 455–465 (1992).
- Rhim AD , StangerBZ. Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog. Mol. Biol. Transl. Sci.97, 41–78 (2010).
- Cheng F , YangZ, HuangF, YinL, YanG, GongG. MicroRNA-107 inhibits gastric cancer cell proliferation and metastasis by targeting PI3K/AKT pathway. Microb. Pathog.121, 110–114 (2018).
- Sharma P , SainiN, SharmaR. miR-107 functions as a tumor suppressor in human esophageal squamous cell carcinoma and targets Cdc42. Oncol. Rep.37(5), 3116–3127 (2017).
- Wang P , LiuX, ShaoYet al. MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor. Oncotarget8(34), 57012–57023 (2017).
- Lu C , XieZ, PengQ. miRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am. J. Cancer Res.7(9), 1863–1873 (2017).
- Sharma P , SarayaA, GuptaP, SharmaR. Decreased levels of circulating and tissue miR-107 in human esophageal cancer. Biomarkers18(4), 322–330 (2013).
- Chen L , ZhangR, LiPet al. p53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2. Neurosci. Lett.534, 327–332 (2013).
- Li X-Y , LuoQ-F, WeiC-K, LiD-F, LiJ, FangL. miRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer. Int. J. Clin. Exp. Med.7(1), 32–40 (2014).
- Molina-Pinelo S , CarneroA, RiveraFet al. miR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer14, 656 (2014).
- Chen L , LiZ, XuSet al. Upregulation of miR-107 inhibits glioma angiogenesis and VEGF expression. Cell. Mol. Neurobiol.36(1), 113–120 (2016).
- Wang S , MaG, ZhuHet al. miR-107 regulates tumor progression by targeting NF1 in gastric cancer. Sci. Rep.6, 36531 (2016).
- Xiong J , WangD, WeiAet al. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN. Exp. Cell Res.361(2), 316–323 (2017).
- Imamura T , KomatsuS, IchikawaDet al. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Sci. Rep.7(1), 5708 (2017).
- Mazur PK , EinwächterH, LeeMet al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl Acad. Sci. USA107(30), 13438–13443 (2010).
- Saito S , IshiguroH, KimuraMet al. Clinical significance of NOTCH1 intracellular cytoplasmic domain translocation into the nucleus in gastric cancer. Biomed. Rep.5(3), 344–348 (2016).
- Catanzaro G , SabatoC, RussoMet al. Loss of miR-107, miR-181c and miR-29a-3p promote activation of Notch2 signaling in pediatric high-grade gliomas (pHGGs). Int. J. Mol. Sci.18(12), 2742 (2017).